Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib + BR in previously untreated mantle cell lymphoma
NCT02972840Phase 3Active, not recruiting
- Sponsor
- Acerta Pharma
- Start
- Apr 2017
- Primary completion
- Feb 2027
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial of acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL) (2 arms), sponsored by Acerta Pharma. Primary endpoint: Progression-Free Survival up to 6 years. Started Apr 2017; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02972840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02972840.